Skip to Content

Primary Aldosteronism Testing Rare in Treatment-Resistant HTN

TUESDAY, Dec. 29, 2020 -- Patients with apparent treatment-resistant hypertension are rarely tested for primary aldosteronism, according to a study published online Dec. 29 in the Annals of Internal Medicine.

Jordana B. Cohen, M.D., from the University of Pennsylvania in Philadelphia, and colleagues examined the testing rate for primary aldosteronism and evidence-based hypertension management for treatment-resistant hypertension in a retrospective cohort study. Data were included for 269,010 veterans from the U.S. Veterans Health Administration with apparent treatment-resistant hypertension from 2000 to 2017.

The researchers found that 1.6 percent of patients were tested for primary aldosteronism. The likelihood of testing was increased with an index visit to a nephrologist or an endocrinologist compared with primary care (hazard ratios, 2.05 and 2.48, respectively). There was an association noted between testing and an increased likelihood of initiating mineralocorticoid receptor antagonist (MRA) therapy (hazard ratio, 4.10) and with better blood pressure control over time.

"The consequences of undertesting for primary aldosteronism and underuse of MRAs in patients with apparent treatment-resistant hypertension may be substantial, potentially increasing morbidity and mortality," the authors write. "Our findings suggest an opportunity to introduce innovative practices to meaningfully improve education of providers and increase testing to enhance management in this high-risk patient population."

Abstract/Full Text (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Posted: December 2020

Read this next

Continuing Blood Pressure Meds Safe for Those With COVID-19

WEDNESDAY, Jan. 20, 2021 -- Hospitalized COVID-19 patients can safely continue using blood pressure medications, according to a study published online Jan. 7 in The Lancet...

Ischemic Heart, Hypertensive Disease Deaths Up During COVID-19

TUESDAY, Jan. 12, 2021 -- During the initial phase of the COVID-19 pandemic, there was an increase in deaths caused by ischemic heart disease and hypertensive diseases in the...

Review Confirms Interarm SBP Difference, Mortality Link

FRIDAY, Jan. 8, 2021 -- The associations between interarm differences in systolic blood pressure and all-cause mortality, cardiovascular mortality, and cardiovascular disease have...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.